Susan MD - Viracta Therapeutics Scientific Consultant
| VIRX Stock | USD 0.16 0.02 14.29% |
Insider
Susan MD is Scientific Consultant of Viracta Therapeutics
| Address | 2533 South Coast Highway 101, Cardiff, CA, United States, 92007 |
| Phone | 858 400 8470 |
| Web | https://www.viracta.com |
Viracta Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.572) % which means that it has lost $0.572 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0867) %, meaning that it created substantial loss on money invested by shareholders. Viracta Therapeutics' management efficiency ratios could be used to measure how well Viracta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.95 in 2024. Return On Capital Employed is likely to drop to -2.91 in 2024. At this time, Viracta Therapeutics' Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.6 M in 2024, whereas Total Assets are likely to drop slightly above 54.4 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jason Davis | Virax Biolabs Group | 52 | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 35 | |
| John CPA | Unicycive Therapeutics | 62 | |
| James Foster | Virax Biolabs Group | 39 | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| Ileen Winick | Candel Therapeutics | N/A | |
| Francesca MD | Candel Therapeutics | 46 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| MPA MD | Unicycive Therapeutics | 51 | |
| Jason Amello | Candel Therapeutics | 56 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| Nathan Caffo | Candel Therapeutics | 55 | |
| Wilson Wong | Senti Biosciences | N/A | |
| FMEDSCI MD | Candel Therapeutics | 62 | |
| Seshu Tyagarajan | Candel Therapeutics | 56 | |
| Susan Kahlert | Senti Biosciences | N/A | |
| LLM JD | Candel Therapeutics | 63 | |
| Deborah Knobelman | Senti Biosciences | 50 | |
| James Collins | Senti Biosciences | 58 | |
| Philip Lee | Senti Biosciences | 42 | |
Management Performance
| Return On Equity | -2.09 | ||||
| Return On Asset | -0.57 |
Viracta Therapeutics Leadership Team
Elected by the shareholders, the Viracta Therapeutics' board of directors comprises two types of representatives: Viracta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viracta. The board's role is to monitor Viracta Therapeutics' management team and ensure that shareholders' interests are well served. Viracta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viracta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel CPA, COO, CFO | ||
| Cheryl Madsen, Senior Affairs | ||
| Daniel Chevallard, COO CFO | ||
| Thalia MD, CoFounder | ||
| Patric MBA, Senior Strategy | ||
| Ronald MD, CoFounder Consultant | ||
| George Hillman, CoFounder | ||
| Robert Williams, CoFounder | ||
| Robert McRae, Vice Alliances | ||
| Ayman ElGuindy, Chief Officer | ||
| Mark Rothera, President CEO | ||
| Stewart Brown, Senior Counsel | ||
| Susan MD, Scientific Consultant | ||
| Michael Faerm, Chief Officer | ||
| Lisa Rojkjaer, Chief Officer | ||
| Biljana PharmD, Senior Development |
Viracta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Viracta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.09 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 2.12 M | ||||
| Shares Outstanding | 39.74 M | ||||
| Shares Owned By Insiders | 2.83 % | ||||
| Shares Owned By Institutions | 50.00 % | ||||
| Number Of Shares Shorted | 2.1 M | ||||
| Price To Earning | 2.54 X | ||||
| Price To Book | 3.00 X | ||||
| EBITDA | (46.86 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viracta Stock Analysis
When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.